Lineage’s lead cell delivery clinical program is Renevia®, a medical device that was developed as a replacement for whole adipose tissue in cell assisted lipotransfer (CAL) procedures.
In September 2019, Renevia received a Class III classification with an intended use in adults as a resorbable matrix for the delivery of autologous adipose tissue preparations to restore and/or augment facial volume after subcutaneous fat volume loss for the treatment of facial lipoatrophy. The CE Mark provides Lineage, or its authorized agent, the authority to market and distribute Renevia throughout the European Union (EU) and in other countries that recognize the CE Mark.
Lineage has engaged Sercader Ltd., a European based, life sciences advisory firm, to identify an external commercialization partner with the capabilities and infrastructure to launch and further develop Renevia in the European market (Read more about Lineage’s Cell/Drug Delivery Technology).
We also have investments in public companies AgeX, Inc. (approximately 5%) and OncoCyte Corporation (approximately 24%).
We are a publicly traded company listed on the NYSE American under the symbol LCTX.